29/9 2020 05:48 Aps invest 1
87147 Today, September 29, 2020 (CET), Orphazyme announces the pricing of the global offering at a price per new ordinary share of DKK 70.1844, corresponding to a price of USD 11.00 per ADS
29/9 2020 17:32 Thorkild01 287171 Referat klippet fra Avanza forum:
"We have been in contact with the Orphazyme team. We are reassured about the NDA process with arimoclomol in NPC, just as we are reassured about our confidence in arimoclomol as a potential efficacious therapy in this underserved indication. We reiterate our probability rate of high 95% in NPC. Our Base Case at DKK 170 per share stands.
Regarding the US listing process, we hope to let it have its go and come back with a research note when we know the outcome. So far, the process seems to have put even further pressure on the stock, currently trading well below our Bear Case of DKK 95 per share. In the light of this, it is important for investors to adopt the broader picture; A potential US IPO, together with the current cash position and the potential sale of a Priority Review Voucher, could support the company's operations until cash positive. This is not to mention the equity story that investor buys into the stock; a late-stage orphan pipeline with multiple shots on goal."
"We have been in contact with the Orphazyme team. We are reassured about the NDA process with arimoclomol in NPC, just as we are reassured about our confidence in arimoclomol as a potential efficacious therapy in this underserved indication. We reiterate our probability rate of high 95% in NPC. Our Base Case at DKK 170 per share stands.
Regarding the US listing process, we hope to let it have its go and come back with a research note when we know the outcome. So far, the process seems to have put even further pressure on the stock, currently trading well below our Bear Case of DKK 95 per share. In the light of this, it is important for investors to adopt the broader picture; A potential US IPO, together with the current cash position and the potential sale of a Priority Review Voucher, could support the company's operations until cash positive. This is not to mention the equity story that investor buys into the stock; a late-stage orphan pipeline with multiple shots on goal."
30/9 2020 09:13 Bador 087179 Stor forskel på kursen. Den amerikanske kurs svarende til godt 70 kr. lå betragteligt under den danske på godt 74 kr. igår. Siden har den bevæget sig nedad - men det har den amerikanske også!
Det der undrer mig, er, at den danske stadig ligger væsentligt over den amerikanske? Vil man ind i Orphazymes, er den billigste vej Nasdaq.
Det der undrer mig, er, at den danske stadig ligger væsentligt over den amerikanske? Vil man ind i Orphazymes, er den billigste vej Nasdaq.
30/9 2020 11:18 Helge Larsen/PI-redaktør 187181 Orphazymes: Den amerikanske notering kan skaffe mere risikovillige investorer:
https://www.proinvestor.com/investornyt/668028/nasdaq-chef-dobbeltnotering-kan-skaffe-mere-risikovillige-investorer
https://www.proinvestor.com/investornyt/668028/nasdaq-chef-dobbeltnotering-kan-skaffe-mere-risikovillige-investorer
Men det hele skete igår, og der er stadig ikke fodslag mellem kurserne. Jeg kan ikke gennemskue hvorfor.
30/9 2020 18:25 187210 Bador - Jeg kan huske da Zealand blev noteret på det amerikanske marked, var der også en del forskel på kursen, ofte blev der ikke handlet så mange aktier, tror ikke det er noget man skal tillægge så stor betydning pt.
1/10 2020 13:03 187226 Kunne Orphazyme mon lave en Zealand?
Goldmann Sachs, gør det vi andre ikke må,
køber 3 stk. hver 10 sek.
Goldmann Sachs, gør det vi andre ikke må,
køber 3 stk. hver 10 sek.
